About: Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Sector: Healthcare
Industry: Biotechnology
Latest price: $44.32 (-0.07%)
IMVTNASDAQImmunovant Inc
Loading watchlist status…
Immunovant Inc share price
IMVT price activity
Last Price
Change (24hr)
USD (%)
Volume
-
Volume (4w avg)
-
Previous Close
N/A
Last Trade
IMVT price performance
6,05%
5D
11,1%
1M
74,47%
YTD
199,26%
1Y
IMVT price fundamentals
N/A
Shares Issued
N/A
Earnings Per Share (EPS)
N/A
Dividends Per Share (DPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
US-NASDAQ rank
N/ASector Rank
N/Aquote.marketSignals